RALEIGH, N.C., Nov. 28, 2016 /PRNewswire/ -- Innovate Biopharmaceuticals Inc., a clinical stage biotechnology company with two drug candidates entering clinical trials for the treatment of celiac disease and ulcerative colitis, will make a presentation at the 28th Annual Piper Jaffray Healthcare Conference in New York this week.
The presentation is scheduled for Tuesday, Nov. 29, at 3 p.m. at the Lotte New York Palace Hotel at 50th St. and Madison Avenue.
Company executives will also meet with interested investors on Nov. 29-30. Investors can email the company to schedule one-on-one meetings on Nov. 29: [email protected].
About Innovate Biopharmaceuticals Inc.Innovate is a privately held, clinical stage biotechnology company focused on developing novel autoimmune/inflammation medicines.
Innovate's lead drug candidate, Larazotide acetate (INN-202), is a novel oral peptide that has consistently reduced clinical symptoms of celiac disease in multiple clinical trials testing more than 800 patients. Larazotide has completed a large phase 2b study and will start Phase 3 trials in 2017. Larazotide's unique mechanism of action of reducing antigen trafficking across epithelial cells makes it a promising therapeutic for multiple diseases involving "leaky tight junctions."
Innovate's second therapeutic in clinical development, INN-108, is an oral small molecule entering Phase 2 trials for the treatment of adult orphan ulcerative colitis as well as mild to moderate ulcerative colitis. INN-108 is a prodrug that only becomes activated in the colon. The convenience of a liquid formulation will be important to children and the aging.
Forward Looking StatementsThis release contains forward-looking statements, including statements regarding the clinical development of our product candidates, which are subject to risks and uncertainties that could cause actual results to differ materially. Reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements, amongst others. These forward-looking statements speak only as of the date hereof. Innovate Biopharmaceuticals disclaims any obligation to update these forward-looking statements.
Advertisement
The presentation is scheduled for Tuesday, Nov. 29, at 3 p.m. at the Lotte New York Palace Hotel at 50th St. and Madison Avenue.
Advertisement
Company executives will also meet with interested investors on Nov. 29-30. Investors can email the company to schedule one-on-one meetings on Nov. 29: [email protected].
About Innovate Biopharmaceuticals Inc.Innovate is a privately held, clinical stage biotechnology company focused on developing novel autoimmune/inflammation medicines.
Innovate's lead drug candidate, Larazotide acetate (INN-202), is a novel oral peptide that has consistently reduced clinical symptoms of celiac disease in multiple clinical trials testing more than 800 patients. Larazotide has completed a large phase 2b study and will start Phase 3 trials in 2017. Larazotide's unique mechanism of action of reducing antigen trafficking across epithelial cells makes it a promising therapeutic for multiple diseases involving "leaky tight junctions."
Innovate's second therapeutic in clinical development, INN-108, is an oral small molecule entering Phase 2 trials for the treatment of adult orphan ulcerative colitis as well as mild to moderate ulcerative colitis. INN-108 is a prodrug that only becomes activated in the colon. The convenience of a liquid formulation will be important to children and the aging.
Forward Looking StatementsThis release contains forward-looking statements, including statements regarding the clinical development of our product candidates, which are subject to risks and uncertainties that could cause actual results to differ materially. Reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements, amongst others. These forward-looking statements speak only as of the date hereof. Innovate Biopharmaceuticals disclaims any obligation to update these forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/innovate-biopharmaceuticals-targeting-celiac-disease-and-ulcerative-colitis-to-present-at-the-piper-jaffray-healthcare-conference-in-new-york-on-tuesday-nov-29-300368748.html
SOURCE Innovate Biopharmaceuticals Inc.
